{
    "clinical_study": {
        "@rank": "82323", 
        "acronym": "SNIF", 
        "arm_group": [
            {
                "arm_group_label": "Healthcare Worker Administration", 
                "arm_group_type": "Other", 
                "description": "FluMist administered by a Healthcare Worker"
            }, 
            {
                "arm_group_label": "Self-Administration", 
                "arm_group_type": "Experimental", 
                "description": "FluMist self-administered by subject"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity\n      of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with\n      healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group\n      self-administration of LAIV."
        }, 
        "brief_title": "Self-Administered Nasal Influenza Feasibility Study", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or healthy, non-pregnant females\n\n          -  18-49 years of age\n\n          -  Department of Defense beneficiary including active duty members\n\n          -  Able to speak and understand English, and provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to eggs, egg-proteins, gentamicin, gelatin, or arginine or\n             life-threatening reactions to previous influenza vaccination\n\n          -  Prior receipt of the 2012-2013 seasonal influenza vaccine for 2012-2013 season or\n             prior receipt of the 2013-2014 seasonal influenza vaccine for 2013-2014 season\n\n          -  Known clinical diagnosis of reactive airway disease, wheezing, or asthma (excluding\n             exercise-induced asthma)\n\n          -  Reported febrile upper respiratory illness (oral or tympanic temperature greater than\n             100\u00b0F or a subjective fever) at the time of or within the 24 hours prior to\n             immunization\n\n          -  Known to be pregnant, possibly pregnant or breast-feeding\n\n          -  Known diagnosis of human immunodeficiency virus (HIV) infection, chronic active\n             hepatitis B infection, or chronic hepatitis C infection\n\n          -  History of Guillain-Barre Syndrome\n\n          -  Household member known to be immunocompromised (either a known disease or disorder\n             such as HIV, or other acquired or congenital immunodeficiency disorder, or taking\n             systemic steroids (any dose) or high daily dose inhaled steroids, tumor necrosis\n             factor-alpha inhibitors, or monoclonal antibodies used to treat autoimmune disease)\n\n          -  Receipt of medications with activity against influenza A and/or B (ex: Tamiflu\u00ae,\n             Relenza\u00ae, amantadine, or rimantadine) within 48 hours prior to vaccine administration\n\n          -  Use of any oral or intravenous systemic steroids (any dose) or any daily dose inhaled\n             steroids\n\n          -  At the time of enrollment, any person who is trained to administer intranasal\n             vaccines or who has been involved in any recurring role associated with the\n             administration of intranasal vaccines to others in the clinic or military treatment\n             facility (MTF)\n\n          -  Prior participation in this research study\n\n          -  Any acute or chronic medical condition that, in the opinion of the investigator,\n             would render vaccination unsafe, interfere with the evaluation of responses, or\n             render the subject unable to meet the requirements of the protocol. These conditions\n             may include, but are not limited to: history of significant renal impairment\n             (dialysis and treatment for kidney disease, including diabetic and hypertensive\n             kidney disease); poorly controlled diabetes mellitus or patients with diabetes\n             mellitus on insulin (subjects with well-controlled diabetes mellitus on oral agents\n             may enroll  as long there has been no dosage increase within the past 6 months);\n             cardiac insufficiency, if heart failure is present; an arteriosclerotic event during\n             the 6 months prior to enrollment (e.g., history of myocardial infarction, stroke,\n             recanalization of femoral arteries, or transient ischemic attack).\n\n          -  If the individual received a live virus vaccine (e.g., Varicella,\n             Measles-Mumps-Rubella, Yellow Fever, Smallpox) in the past 4 weeks, they should wait\n             28 days before receiving LAIV. There is no reason to defer vaccination if the\n             individual was vaccinated with an inactivated vaccine or if they have recently\n             received blood or other antibody-containing blood products."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933048", 
            "org_study_id": "IDCRP-070"
        }, 
        "intervention": {
            "arm_group_label": [
                "Healthcare Worker Administration", 
                "Self-Administration"
            ], 
            "description": "FluMist Intranasal Vaccine", 
            "intervention_name": "FluMist", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "influenza", 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92134"
                    }, 
                    "name": "Naval Medical Center San Diego"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Sam Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78234"
                    }, 
                    "name": "San Antonio Military Health System"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Self-Administered Nasal Influenza Vaccine: Immunogenicity and Feasibility of Group Administration", 
        "other_outcome": {
            "description": "reactogenicity outcomes captured in the first 7 days post-vaccination as well as responses to study questionnaires that assess preference for HCWA-LAIV versus SA-LAIV, the proportion of SA-LAIV vaccinees reporting difficulties solicited through the questionnaire, and evaluating the time required for vaccine administration using metrics such as aggregate or mean time of vaccine administration for HCWA and SA subjects", 
            "measure": "Feasibility Measures", 
            "safety_issue": "Yes", 
            "time_frame": "28 +/- 7 days post vaccination"
        }, 
        "overall_official": {
            "affiliation": "Uniformed Services University of the Health Sciences", 
            "last_name": "Timothy Burgess, MD, MPH, Capt, MC, USN", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Post-vaccination geometric mean titer ratios between HCWA and SA subjects", 
            "safety_issue": "No", 
            "time_frame": "28+/- 7 days post-vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933048"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Uniformed Services University of the Health Sciences", 
            "investigator_full_name": "Timothy Burgess", 
            "investigator_title": "Captain, Medical Corps, US Navy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "proportion with seroresponse, defined as the percentage of subjects achieving a post-vaccination hemagluttinin antibody inhibition (HAI) titer \u2265 1:40\nproportion with seroconversion, defined as the percentage of subjects with either a pre-vaccination HAI titer < 1:10 and a post vaccination HAI titer \u2265 1:40 or a pre-vaccination HAI titer \u2265 1:10 and a minimum four-fold rise in post-vaccination HAI titer", 
            "measure": "Difference and Proportion in Seroresponse and Seroconversion", 
            "safety_issue": "No", 
            "time_frame": "28+/- 7 days post-vaccination"
        }, 
        "source": "Uniformed Services University of the Health Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Uniformed Services University of the Health Sciences", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}